Dual specificity antibodies and methods of making and using

Details for Australian Patent Application No. 2007202323 (hide)

Owner Abbott Laboratories

Inventors Dixon, Richard; Ghayur, Tariq; Collinson, Albert; Kaymakcalan, Zehra; Avgerinos, George

Agent Spruson & Ferguson

Pub. Number AU-B-2007202323

Parent 2001271636

Filing date 23 May 2007

Wipo publication date 14 June 2007

Acceptance publication date 15 December 2011

International Classifications

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61K 49/00 (2006.01) Preparations for testing

A61P 1/04 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 17/06 (2006.01) Drugs for dermatological disorders

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 1/15 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 1/19 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 1/21 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

C12P 21/08 (2006.01) Preparation of peptides or proteins - Monoclonal antibodies

G01N 33/15 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Medicinal preparations

G01N 33/53 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Immunoassay

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

7 June 2007 Complete Application Filed

14 June 2007 Application Open to Public Inspection

  Published as AU-B-2007202323

15 December 2011 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 29 Nov 2011. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

15 December 2011 Application Accepted

  Published as AU-B-2007202323

12 April 2012 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 29 Nov 2011

12 April 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007202324-Treating muscle wasting with selective androgen receptor modulators

2007202322-Improved closed suction catheter assembly adaptor and system containing the same